Cover Image
市場調查報告書

受體型蛋白酪氨酸激酶ERBB4:開發中產品分析

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363580
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
受體型蛋白酪氨酸激酶ERBB4:開發中產品分析 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 111 Pages
簡介

本報告提供糖原合成酵素激酶β (GSK3β)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

糖原合成酵素激酶β (GSK3β)的概要

治療藥的開發

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各開發階段

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各治療範圍

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各適應症

糖原合成酵素激酶β (GSK3β):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

糖原合成酵素激酶β (GSK3β):企業開發中的產品

糖原合成酵素激酶β (GSK3β):大學/機關開發中的產品

糖原合成酵素激酶β (GSK3β):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

糖原合成酵素激酶β (GSK3β)的治療藥的開發企業

  • AMO Pharma Limited
  • Angelini Group
  • Celon Pharma Sp. z o.o.
  • DiaMedica Inc.
  • HitGen LTD
  • Jeil Pharmaceutical Co., Ltd.
  • 田邊三菱製藥
  • Neurim Pharmaceuticals Ltd

藥物簡介

糖原合成酵素激酶β (GSK3β):暫停中的計劃

糖原合成酵素激酶β (GSK3β):開發中止的產品

糖原合成酵素激酶β (GSK3β):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0222TDB

Summary

Global Markets Direct's, 'Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) Overview
  • Therapeutics Development
    • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Stage of Development
    • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Therapy Area
    • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Indication
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Companies
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Products under Development by Universities/Institutes
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Aslan Pharmaceuticals Pte. Ltd.
    • Boehringer Ingelheim GmbH
    • GamaMabs Pharma S.A.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • HEC Pharm Co., Ltd.
    • Jiangsu Kanion Pharmaceutical Co., Ltd.
    • Minerva Neurosciences, Inc.
    • Pfizer Inc.
    • Puma Biotechnology, Inc.
    • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dacomitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FCN-411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIN-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize HER4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neratinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neucardin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRG-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-357 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • poziotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKLB-1206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • varlitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yinlitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Projects
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Featured News & Press Releases
    • Jun 05, 2016: Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
    • May 18, 2016: Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
    • May 09, 2016: The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer
    • Apr 21, 2016: New Data On Aslan's Varlitinib To Be Published At 2016 Annual Meeting Of American Society Of Cancer Oncology
    • Apr 20, 2016: Puma Biotechnology's Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016
    • Apr 15, 2016: FDA approves Gilotrif (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung
    • Apr 14, 2016: Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
    • Apr 13, 2016: Head-to-head study demonstrating Gilotrif (afatinib) significantly improved clinical outcomes compared to Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology
    • Apr 07, 2016: Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
    • Apr 04, 2016: Precision medicine brings new hope to those with advanced urothelial cancer
    • Mar 28, 2016: Puma Biotechnology Updates Timeline for Filing New Drug Application For Neratinib
    • Mar 18, 2016: Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
    • Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
    • Feb 29, 2016: European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung
    • Feb 23, 2016: Aslan Pharmaceuticals To Present New Data On Varlitinib At Annual American Association For Cancer Research Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by GamaMabs Pharma S.A., H1 2016
  • Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by Minerva Neurosciences, Inc., H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Puma Biotechnology, Inc., H1 2016
  • Pipeline by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., H1 2016
  • Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top